Equities
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Carl Zeiss Meditec AG had net income fall -20.99% from 178.73m to 141.21m despite a 7.82% increase in revenues from 2.07bn to 2.23bn. An increase in the selling, general and administrative costs as a percentage of sales from 27.55% to 28.12% was a component in the falling net income despite rising revenues.
Gross margin52.19%
Net profit margin5.53%
Operating margin8.91%
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in EURView more

In 2025, Carl Zeiss Meditec AG increased its cash reserves by 34.42%, or 6.98m. The company earned 209.86m from its operations for a Cash Flow Margin of 9.42%. In addition the company used 91.03m on investing activities and also paid 108.83m in financing cash flows.
Cash flow per share--
Price/Cash flow per share--
Book value per share--
Tangible book value per share--
More ▼

Balance sheet in EURView more

Carl Zeiss Meditec AG uses little or no debt in its capital structure.
Current ratio--
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼

Growth rates in EUR

SmartText is unavailable
Div yield(5 year avg)0.90%
Div growth rate (5 year)1.92%
Payout ratio (TTM)39.92%
EPS growth(5 years)3.35
EPS (TTM) vs
TTM 1 year ago
-22.63
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.